Ethic Inc. Novo Cure LTD Transaction History

Ethic Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$56.44 - $118.81 $199,910 - $420,825	3,542 New	3,542 $213,000
Q2 2022 Aug 10, 2022	SELL	$56.6 - $89.9 $148,858 - $236,437	-2,630 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $14,616 - $20,538	-243 Reduced 8.46%	2,630 $218,000
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $18,094 - $29,399	241 Added 9.16%	2,873 $216,000
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $136,267 - $228,207	-1,173 Reduced 30.83%	2,632 $306,000
Q2 2021 Aug 10, 2021	BUY	$130.4 - $225.58 $288,836 - $499,659	2,215 Added 139.31%	3,805 $844,000
Q1 2021 May 13, 2021	BUY	$124.11 - $190.17 $197,334 - $302,370	1,590 New	1,590 $210,000

266

73.8M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.34B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Ethic Inc., based on Form 13F filings with the SEC.

Stay updated on Ethic Inc. with notifications on news.